Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology

Advanced Drug Delivery Reviews

Volumn 63, Issue 6, 2011, Pages 427-440

  Merisko Liversidge, Elaine ^a   Liversidge, Gary G ^a  

^a Elan Drug Technologies   (United States)

Author keywords

Nanomedicine; Nanoparticles; Nanosuspensions; Poorly water soluble compounds

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; CONVENTIONAL APPROACH; COSOLVENTS; DOSAGE FORMS; DRUG CONCENTRATION; DRUG SUBSTANCES; MEAN DIAMETER; MILLING PROCESS; NANO-DISPERSIONS; NANO-PARTICLE DISPERSIONS; NANOMEDICINES; NANOMETER-SIZED PARTICLES; NANOSIZING; NANOSUSPENSIONS; PARTICLE SIZE REDUCTION; PATIENT COMPLIANCE; PERFORMANCE ISSUES; POORLY-WATER SOLUBLE COMPOUNDS; SCREENING PROGRAMS; SHELF LIFE; SIDE EFFECT; SOLID DOSAGE FORMS; WATER SOLUBLE COMPOUNDS; WATER-BASED MEDIA; WET MEDIA;

BIOCHEMISTRY; DRUG DELIVERY; DRUG DOSAGE; MEDICAL NANOTECHNOLOGY; MILLING (MACHINING); NANOPARTICLES;

DRUG PRODUCTS;

ADIPIODONE; ANTHRACENE; APREPITANT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CAMPTOTHECIN; CILOSTAZOL; CINNARIZINE; CURCUMIN; DANAZOL; DIAZOACETIC ACID ETHYL ESTER; ETOPOSIDE; EXCIPIENT; GRISEOFULVIN; HYDROCORTISONE ACETATE; IBUPROFEN; INDOMETACIN; ITRACONAZOLE; KETOPROFEN; LOVIRIDE; MEGESTROL ACETATE; NAPROXEN; NIFEDIPINE; PACLITAXEL; PHENYLBUTAZONE; PHENYTOIN; POSACONAZOLE; PREDNISOLONE ACETATE; RILPIVIRINE; UNINDEXED DRUG;

ANOREXIA; AREA UNDER THE CURVE; BINDING AFFINITY; CACHEXIA; DISPERSION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDUSTRY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; GRINDING; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SHELF LIFE; STATIC ELECTRICITY; SUSPENSION; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; INFUSIONS, PARENTERAL; NANOPARTICLES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 79957861493     PISSN: 0169409X     EISSN: 0169409X     Source Type: Journal    
DOI: 10.1016/j.addr.2010.12.007     Document Type: Review

References (153)

1. Krishnaiah Y.S.R. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J. Bioequivalence Bioavailability 2010, 2:28-36.
2. Fahr A., Liu X. Drug delivery strategies for poorly-water soluble drugs. Expert Opin. Drug Deliv. 2007, 4:403-416.
3. Giliyar C., Fickstad D.T., Tyavanagimatt S. Challenges and opportunities in oral delivery of poorly-water soluble drugs. Drug Deliv. Technol. 2006, 6:57-63.
4. Giliyar C., Fikstad D.T., Tyavanagimatt S. Solubilization technologies-challenges & opportunities in oral drug delivery of poorly water-soluble drugs. Drug Deliv. Technol. 2006, 6:57-63.
5. Chong-Kook K., Park J.-S. Solubility enhancers for oral drug delivery. Am. J. Drug Deliv. 2004, 2:113-130.
6. Stegemann S., Leveiller F., Franchi D., deJong H., Linden H. When poor solubility becomes an issue: from early stage to proof of concept. Eur. J. Pharm. Sci. 2007, 31:249-261.
7. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 2000, 89:145-154.
8. Benet L.Z., Amidon G.L., Barends D.M., Lennern A.H., Polli J.E., Shah V.P., Stavchansky S.A., YU L.X. The use of BDDCS in classifying the permeability of marketed drugs. Pharm. Res. 2008, 25:483-488.
9. Dressman J., The B.C.S. Where do we go from here?. Pharm. Technol. 2001, 25:68077.
10. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
11. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2004, 50:47-60.
12. Sethia S., Squillante E. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier 2003, 20:215-247.
13. Gullapalli R.P. Soft gelatin capsules (softgels). J. Pharm. Sci. 2010, 1-42.
14. Stella V., Qanren H. Cyclodextrins. Toxicol. Pathol. 2008, 36:30-42.
15. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Dis. 2004, 3:1023-1035.
16. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 2002, 54:107-117.
17. Bittner B., Mountfield R.J. Intravenous administration of poorly water soluble New drug entities in early discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Dev. 2002, 5:59-71.
18. Davis S.S., Washington C., Illus L., Liversidge G.G., Sternson L., Kirsh R. Lipid emulsions as drug delivery systems. Ann. NY Acad. Sci. 1987, 507:75-88.
19. Kawakami K., Yoshikawa T., Moroto Y., et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs: I. Prescription Design. J. Control. Release 2002, 81:75-82.
20. Pouton C.W. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. 2000, 11(Supplement 2):93-98.
21. Fenske D.B., Chonn A., Cullis P.R. Liposomal nanomedicine: an emerging field. Toxicol. Pathol. 2008, 36:21-29.
22. Malam Y., Yogesh K., Loizidou M., Seifalian A. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30:592-599.
23. Mohanty C., Acharya S., Sahoo S., Sanjeeb K. Micelles: the multifunctional nanocarrier for colloidal drug delivery. Surfactant Sci. Ser. 2010, 148:157-175. (Colloids in Drug Delivery).
24. Liversidge G., Cundy K. Particle size reduction for the improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in Beagle dogs. Int. J. Pharm. 1995, 125:91-97.
25. Muller R.H. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect in the future. Adv. Drug Deliv. Rev. 2001, 47:3-19.
26. Keck C.M., Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
27. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
28. Pu X., Sun J., Li M., He Z. Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs. Curr. Nanosci. 2009, 5:417-427.
29. Timpe C. Drug solubilization strategies applying nanoparticulate formulation and solid dispersion approaches, drug development. Pharm. Rev. 2010, 13:12-21.
30. Gao L., Zhang D., Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 2008, 10:845-846.
31. Pathak P., Meziani M.J., Sun Y.-P. Supercritical fluid technology for enhanced drug delivery. Expert Opin. Drug Deliv. 2005, 2:747-761.
32. Panagiotou T., Fisher R.J. Form nanoparticles via controlled crystallization. Chem. Eng. Prog. 2008, 33-39.
33. Joshi M.D., Muller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 72:370-377.
34. Green M., Manikhas G., Orlov S., Afanasyev B., Makhson A., Bhar P. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Annu. Oncol. 2006, 17:1263-1268.
35. Overhoff K.A., Engstrom J.D., Chen B., Scherzer B.D., Milner T.E., Johnston K.P., Williams R.O. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly-water soluble drugs. Eur. J. Pharm. Biopharm. 2007, 65:57-67.
36. Matteucci M., Paguio J.C., Miller M.A., Williams R.O., Johnston K.P. Flocculated amorphous nanoparticles for highly supersaturated solutions. Pharm. Res. 2008, 25:2477-2487.
37. Bottomley K. Nanotechnology for drug delivery: a validated technology?. Drug Deliv. Rep. Autumn/Winter 2006, 20-21.
38. Van Eerdenbrugh B., Van den Moorter G., Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 2008, 364:64-75.
39. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
40. Wu W., Nancollas H. A new understanding of the relationship between solubility and particle size. J. Solut. Chem. 1998, 27:521-531.
41. Godec A., Gaberscek M., Jamnik J. Comment of the article "A new understanding of the relationship between solubility and particle size". J. Solut. Chem. 2009, 38:135-146.
42. Borm P., Klaessig F.C., Landry T.D., Moudgil B., Pauluhn J., Thomas K., Trottier R., Wood S. Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci. 2006, 90:23-32.
43. Tang R., Orme C.A., Nancollas G.H. Dissolution of crystallites: surface energetic control and size effects. Chem. Phys. Chem. 2004, 5:688-696.
44. Alsenz J., Kansy M. High throughput solubility measurement in drug discovery and development. Adv. Drug Deliv. Rev. 2007, 59:546-567.
45. Li P., Zhao L. Developing early formulations: practice and perspective. Int. J. Pharm. 2007, 341:1-19.
46. Lipinski C.A. Poor aqueous solubility: an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5:82-85.
47. Takagi T., Ramachandran C., Bermejo M., Yamashita S., Yu L.X., Amidon G.L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol. Pharm. 2006, 3:631-643.
48. Lipinski C.A. Avoiding investment in doomed drugs: is poor solubility an industry wide problem?. Curr. Drug Discov. April 2001, 17-19.
49. Lipinski C.A. Filtering in drug discovery. Annu. Rep. Comput. Chem. 2005, 1:155-168.
50. Lipper R.A. E Pluribus product. Mod. Drug Discovery 1999, 2:55-60.
51. Pharmaceutical research and manufacturers of America, based on Tufts Center for the Study of Drug Development http://www.innovation.org/index.cfm/ToolsandResources/FactSheets/Innovat ion_by_the_Numbers#6-PhRMA.
52. J. Cunningham, E. Liversidge, E.R. Cooper, G.G. Liversidge, Milling microgram quantities of nanoparticulate candidate compounds. United States Patent Application No. US2044/0173696 (2004).
53. Juhnke M., Berghausen J., Timpe C. Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach. Chem. Eng. Technol. 2010, 33:1412-1418.
54. R.G. Reed, D.A. Czekai, H.W. Bosch, N.P. Ryde, T. Ryde, Small scale mill and methods thereof. United States Patent No. 6,431,478 (2002).
55. Lindner S. The effect of grinding media performance on milling a water-based color pigment. Chem. Eng. Technol. 2010, 33:1456-1463.
56. Merisko-Liversidge E., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
57. Knieke C., Sommer M., Peukert W. Identifying the apparent and true grinding limit. Powder Technol. 2009, 195:25-30.
58. Knieke C., Steiborn C., Romeis S., Peukert W., Breitung-Faes S., Kwade Arno Nanoparticle production with the stirred-media mills: opportunities and limits. Chem. Eng. Technol. 2010, 33:1401-1411.
59. Derjaguin B.V., Landau L. Theory of the stability of strongly charged lyophobic sols and the adhesion of strongly charged particles in solutions of electrolytes. Acta Phys. Chem. 1941, 14:633-662.
60. Verwey E.J.W., Overbeek J.Th.G. Long distance forces acting between colloidal particles. Trans. Faraday Soc. 1946, 42B:117-123.
61. Bostrom M., Williams D.R.M., Ninham B.W. Specific Ion effects: why DLVO theory fails for biology and colloid systems. Phys. Rev. Lett. 2001, 87:168103/1-168103/4.
62. G.G. Liversidge, K.C. Cundy, J.F. Bishop, D.A. Czekai, Surface modified drug nanoparticles, United States No. 5,145,684 (1992).
63. Choi J.-Y., Yoo J.Y., Kwak H.-S., Nam B.U., Lee J. Role of polymeric stabilizers for drug nanocrystal dispersions. Curr. Appl Phys. 2005, 472-474.
64. Verma S., Huey B.D., Burgess D. Scanning probe microscopy method for nanosuspension stabilizer selection. Langmuir 2009, 25:12481-12487.
65. Lee J., Lee S.-J., Choie J.-Y., Yoo J.Y., Ahn C.-H. Amphophilic amino acid co-polymers as stabilizers for the preparation of nanocrystal dispersion. Eur. J. Pharm. Sci. 2005, 24:441-449.
66. J. Cunningham, E. Merisko-Liversidge, Nanoparticulate compositions having a peptide as surface stabilizer. PCT. INT. Appl. No. WO 2005044234 (2005).
67. Moschwitzer J., Muller R.H. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur. J. Pharm. 2006, 62:282-287.
68. Batrakova E., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
69. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 2007, 59:631-644.
70. Yamada T., Saito N., Imai T. Effect of grinding with hydroxypropyl cellulose on the dissolution and particle size of a poorly water-soluble drug. Chem. Pharm. Bull. 1999, 47:1311-1313.
71. Van Eerdenbrugh B., Vermant J., Martens J.A., Froyen L., Van Humbeeck J., Augustijns P., Van dem Mooter G. A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 2009, 98:2091-2103.
72. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J.M., Pugh L., Polin L., Jones J., Corbett T., Cooper E., Liversidge G.G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 1996, 13:272-278.
73. Pace S., Pace G.W., Parikh I., Misra A. Novel injectable formulations of insoluble drugs. Pharm. Technol. 1999, 23:116-134.
74. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., Ning J. Suspensions for intravenous (IV) injection: a review of the development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 2008, 60:939-954.
75. Strickley R.G. Parenteral formulations of small molecules therapeutics marketed in the United States (1999)-part II. J. Pharm. Sci. Technol. 2000, 54:69-95.
76. Ostwald W. Studien uber die bildung und Umwandlung fester Korper. Z. Phys. Chem. 1897, 22:289.
77. Boistelle R., Astier J.P. Crystallization mechanisms in solution. J. Cryst. Growth 1988, 90:14-30.
78. Gwozdz G. A perfect formulation. Pharm Qual. April/May 2009, 28-32.
79. Megace® ES Prescribing Information, Par Pharmaceutical Companies, Inc. 2005.
80. Dressman J.B., Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 2:S73-S80.
81. Yalkowsky S.H., Krzyzaniak J.F., Ward G.H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87:787-796.
82. Armwit P., Kerdcharoen T., Qi H. In vitro plasma compatibility of a nanosuspension formulation, PDA. J. Pharm. Sci. Technol. 2006, 60:211-217.
83. E. Liversidge, L. Wei, Stabilization of chemical compounds using nanoparticulate formulations, United States Patent Application No. 2003054042 (2003).
84. Moschwitzer J., Achleitner G., Pomper H., Muller R. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 2004, 58:615-619.
85. Vippagunta S.R., Brittain H.G., Grant D.J.W. Crystalline solids. Adv. Drug Deliv. Rev. 2001, 48:3-21.
86. Bunjes H., Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev. 2007, 59:379-402.
87. R.A. Jain, S.B. Ruddy, K.I. Cummings, M.J. Clancy, J.E. Codd, Rapidly disintegrating solid oral dosage, United States Patent Application No. 2004/0057993 (2004).
88. Schmidt C., Bodmeier R. Incorporation of polymeric nanoparticles into solid dosage forms. J. Control. Release 1999, 57:115-125.
89. Nekkanti V., Pillai R., Venkateshwarlu V., Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm. Dev. Technol. 2009, 14:290-298.
90. Chaubal M.V., Popescu C. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm. Res. 2008, 25:2302-2308.
91. Van Eerdenbrugh B., Froyen L., Van Humbeck J., Martens J.A., Augustinjns P., Van den Mooter G. Drying crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur. J. Pharm. Sci. 2008, 35:127-135.
92. Basa S., Muniyappan T., Karatgi P., Prabhu R., Pillai R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev. Ind. Pharm. 2008, 34:1209-1218.
93. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 2006, 58:1688-1713.
94. E.R. Cooper, J.A. Bullock, J. R. Chippari, J.L. Schaefer, R.A. Patel, R. Jain, J. Strasters, N. Ryde, S. Ruddy, In vitro methods for evaluating the in vivo effectiveness of microparticulate or nanoparticulate active agent compositions, United Sates Patent No. 7, 695, 739 (2010).
95. Heng D., Cutler D.J., Chan H.-K., Yun J., Raper J.A. Dissolution kinetic behavior of drug nanoparticles and their conformity to diffusion model. Langmuir 2008, 24:7538-7544.
96. Heng D., Ogawa K., Cutler D.J., Chan H.-K., Raper J.A., Ye L., Yu J. Pure drug nanoparticles in tablets: what are the dissolution limitations?. J. Nanopart. Res. 2010, 12:1743-1754.
97. N. Ryde, S.B. Ruddy, Solid dosage nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate, United States Patent No. 6, 375, 986 (2002).
98. Van Eerdenbrugh B., Froyen L., Van Himbeeck J., Martens J.A., Augustijns P., Van Den Mooter G. Alternative matrix formers for nanosuspension solidification: dissolution performance and X-Ray microanalysis as an evaluation tool for powder dispersion. Eur. J. Pharm. Sci. 2008, 35:344-353.
99. Vergote G.J., Nervaet C., Van Driessche I., Hoste S., De Smedt S., Demeester J., Jain R.A., Ruddy S., Remon J.P. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int. J. Pharm. 2001, 219:81-87.
100. Kesisoglou F., Panmai S., Wu Y. Application of nanoparticles in oral delivery of immediate release formulations. Curr. Nanosci. 2007, 3:183-190.
101. Vergote G.J., Nervaet C., Van Driessche I., Hoste S., De Smedt S., Demeester J., Jain R.A., Ruddy S., Remon J.P. In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. Int. J. Pharm. 2002, 240:79-84.
102. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in Beagle dogs. J. Control. Release 2006, 111:56-64.
103. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 2004, 285:135-146.
104. Rabinow B.E. Nanosuspension drug delivery. Nat. Rev. Drug Deliv. 2004, 3:785-796.
105. Kipp J.E. The role of solid nanoparticle technology in parenteral delivery of poorly water soluble drugs. Int. J. Pharm. 2004, 284:109-122.
106. Lentz K.A., Quitko M., Morgan D.G., Grace J.E., Gleason C., Marathe P.H. Development and validation of a preclinical food effect model. J. Pharm. Sci. 2007, 96:459-472.
107. Hecq J., Deleers M., Fanara D., Vranckx H., Boulanger P., Lamer S.L., Amighi K. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of UCB-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 2006, 64:360-368.
108. K. Sigfridsson, A.J. Lundqvist, M. Strimfors, Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development, Drug Dev. Industrial Pharm. (In print) Posted online: August 12, 2010 (doi:10.3109/03639045.2010.505927).
109. Akimoto M., Nagahata N., Furuya A., Fukushima K., Higuchi S., Suwa T. Gastric pH profiles of Beagle dogs and their use as an alternative to human testing. Eur. J. Pharm. Biopharm. 2000, 49:99-102.
110. Polentarutt B., Albery T., Dressman J., Abrahamsson B. Modification of gastric pH in the fasted dog. J. Pharm. Pharmacol. 2010, 62:462-469.
111. Liversidge G.G., Merisko-Liversidge E., Ruddy S.B., Callanan F. Will nanoparticles deliver?. Drug Discovery Dev. 2009, 12:30-34.
112. Mouton J.W., Van Peer A., deBeule K., Vliet V., Donnelly J.P., Soons P.A. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob. Agents Chemother. 2006, 50:4096-4102.
113. Kraft W.K., Steiger B., Beussink D., Quiring J.N., Fitzgerald N., Greenberg M.D., Waldman S.A. The pharmacokinetics of nebulized nanocrystal budesonide in healthy volunteers. J. Clin. Pharm. 2004, 44:67-72.
114. Gopal S., Gassmann-Mayer C., Palumbo J., Samtani M.N., Shiwach R., Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr. Med. Res. Opin. 2010, 26:377-387.
115. van't Klooster G., Hoeben E., Borghys H., Looszova A., Bouche M.-P., van Velsen F., Baert L. Pharmacokinetics and deposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 2010, 54:2042-2050.
116. Douglas S.J., Davis S.S., Illum L. Nanoparticles in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3:233-261.
117. Juliano R.L. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Deliv. 1988, 2:31-54.
118. Hamad I., Moghimi S.M. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers, and the bioavailable drug. Expert Opin. Drug Deliv. 2008, 5:205-219.
119. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
120. Litzinger D.C., Buiting A.M.J., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethyleneglycol)-containing liposomes. BBA 1994, 1190:99-107.
121. Sahay G., Alakhova D., Kabanov A.V. Endocytosis of nanomedicines. J. Control. Release 2010, 145:182-195.
122. Chunbai H., Yiping H., Lichen Y., Cui T., Chunhua Y. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
123. Owens D.E., Peppas N.A. Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
124. E. Liversidge, G. A. Gottardy, Use of PEG-derivatized lipids as surface stabilizers for nanoparticulate compositions United States Patent No. 6, 270, 806. (2001).
125. Park K. To PEGylate or not PEGylate, that is not the question. J. Control. Release 2010, 142:147-148.
126. Socha M., Bartecki P., Passitani C., Sapin A., Damge C., Lecompte T., Barre J., Ghazouani E., Maincent P. Stealth nanoparticles coated with heparin as peptide or peptide carriers. J. Drug Target. 2009, 17:575-585.
127. Peltier N.W., Uhl J., Steel V., Brophy L., Merisko-Liversidge E. Direct suppression of phagocytosis by amphipathic surfactants. Pharm. Res. 1992, 9:1177-1183.
128. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., Ning J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 2008, 60:939-954.
129. Engels E.K., Mathot R.A.A., Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007, 18:95-103.
130. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of NAB-paclitaxel compared with solvent-based paclitaxel. Biotechnol. Annu. Rev. 2007, 13:345-357.
131. Stinchcombe T.E. Nanoparticle albumin-bound paclitaxel: a novel cremophor-EL-free formulation of paclitaxel. Nanomedicine 2007, 2:415-423.
132. Cortes J., Saura C. Nanoparticle albumin-bound (NAB)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Suppl. 2010, 8:1-10.
133. Shen L.J., F-L Wu. Nanomedicines in renal transplant rejection-focus on sirolimus. Int. J. Nanomedicine 2007, 2:25-32.
134. Oliver I., Shelukar S., Thompson K.C. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int. J. Nanomedicine 2007, 2:12-18.
135. Gopal S., Gassmann-Mayer C., Palumbo J., Samtani M.N., Shiwach R., Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr. Med. Res. Opin. 2010, 26:377-387.
136. Hoy S.M., Scott L., Keating G.M. Intramuscular paliperidone palmitate. CNS Drugs 2010, 24:227-244.
137. Deschamps B., Musaji N., Gillespie J.A. Food effect on the bioavailability of Two distinct formulations of megesterol acetate oral suspension. Int. J. Nanomedicine 2009, 4:185-192.
138. Acharya G., Shin C.S., McDermott M., Misra H., Park H., Chan K.I., Park K. The hydrogel template method for fabrication of homogeneous nano/microparticles. J. Control. Release 2010, 141:314-319.
139. Caldorea-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 2010, 7:479-495.
140. Liversidge G.G., Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125:309-313.
141. Wiedmann T.S., DeCastro L., Wood R.W. Nebulization of NanoCrystals™: production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm. Res. 1997, 14:112-116.
142. Ain-Ai A., Gupta P.K. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers of the physical stability of high drug loading nanosuspensions of a poorly water soluble compound. Int. J. Pharm. 2008, 351:282-288.
143. Baert L., van 't Klooster G., Dries W., Francois M., Wouters A., Basstanie E., Uterbeke K., Stappers F., Stevens P., Schueller L., Van Remoortere P., Kraus G., Wigerinck P., Rosier J. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 2009, 72:502-508.
144. Ostrander K.D., Bosch H.W., Bondanza D.M. An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 1999, 48:207-215.
145. Zhang J.Y., Bosch H.W. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 1997, 23:1087-1093.
146. Dai W.-G., Dong L.C., Song Y.-Q. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int. J. Pharm. 2007, 342:201-207.
147. Sigfridsson K., Forssen S., Hollander P., Skantze U., de Verdier J. A formulation comparison, using a solution and different nanosuspensions of a poorly water soluble compound. Eur. J. Pharm. Biopharm. 2007, 67:540-547.
148. Chan C.P.-Y., Bruemmel Y., Seydack M., Sin K.-K., Wong L.-W., Merisko_liversidge E., Trau D., Renneberg R. Nanocrystal biolabels with releasable fluorophores for immunoassays. Anal. Chem. 2004, 76:3638-3645.
149. Van Eerdenbrugh B., Froyen L., Martens J.A., Blaton N., Augustijns P., Brewster M., Van den Moorter G. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dries solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 2007, 338:198-206.
150. Van Eerdenbrugh B., Vercruysse S., Martens J.A., Vermant J., Ludo F., Van Humbeeck J., Van den Moorter G., Augustijns P. Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions-a case study with itraconazole. Eur. J. Pharm. Biopharm. 2008, 70:590-596.
151. Fakes M.G., Vakkalagadda B.J., Qian F., Desikan S., Gandhi R.B., Lai C., Hsieh A., Franchini M., Toale H., Brown J. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int. J. Pharm. 2009, 370:167-174.
152. Onoue S., Takahashi H., Kawabata Y., Seto Y., Hatanaka J., Timmermann B., Yamada S. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J. Pharm. Sci. 2009, Published online in Wiley InterScience. http://www.interscience.wiley.com, 10.1002/jps.
153. Na G.C., Stevens H.J., Yuan B.O., Rajagopalan N. Physical stability of ethyl diatrizoate nanocrystalline suspension in stem sterilization. Pharm. Res. 1999, 16:569-574.